As part of the launch of the Pharmaceutical Strategy for Europe, the European Commission is revising the EU pharmaceutical legislation. The revision provides a much-needed opportunity to ensure better access to pharmaceuticals and plasma-derived therapies for patients in the EU. PPTA has contributed to the European Commission consultations as well as participated in the targeted stakeholder consultation and is looking forward to contributing further to the process.
In its contributions, PPTA calls on the European Commission to consider the following aspects during the revision:
For more detail, see PPTA position paper on the evaluation of the EU pharmaceutical legislation.
Please click here to access PPTA feedback to the revision of the EU Pharmaceutical legislation Inception Impact Assessment.